

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		A	TTORNEY DOCKET NO.
09/534,893	03/24/0	D LAZEWATSKY		Ţ".	DM6993
_	HM12/0620 ☐		EXAMINER		
MAUREEN P O BRIEN			.TONESD		
DUPONT PHARMACEUTICAL COMPANY				ART UNIT	PAPER NUMBER
LEGAL PATE 1007 MARKE WILMINGTON	T STREET			1619 DATE MAILED:	9
					06/20/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks



Applicati n No. Applicant(s) LAZEWATSKY, JOEL 09/534.893 Offic Action Summary Examin r **Art Unit** 1619 D. L. Jones -- The MAILING DATE f this communication appears on the c ver sheet with the correspondenc address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). **Status** Responsive to communication(s) filed on _____. 1) 2b) This action is non-final. 2a)□ This action is FINAL. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disp sition of Claims 4) Claim(s) 1-19 is/are pending in the application. 4a) Of the above claim(s) _____ is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) ____ is/are rejected. 7) Claim(s) is/are objected to. 8) Claims 1-19 are subject to restriction and/or election requirement. **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on ____ is/are objected to by the Examiner. 11) The proposed drawing correction filed on _____ is: a) approved b) disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some * c) ☐ None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 18) Interview Summary (PTO-413) Paper No(s). 15) Notice of References Cited (PTO-892)

16) Notice of Draftsperson's Patent Drawing Review (PTO-948)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _

19) Notice of Informal Patent Application (PTO-152)

20) Other:



Application/Control Number: 09/534,893

Art Unit: 1619

ELECTION OF SPECIES

1. Claims 1-19 are generic to a plurality of disclosed patentably distinct species comprising compounds for imaging. In particular, the compounds may be for formula I as set forth in claim 4 comprising the variables Q, d, Ln, Ch', x, MT, AL1, y, z, and AL2. The variables may have definitions ranging from a bond to a heterocyclic ring system (for examples of definitions, see pages 30-32). Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

<u>Note</u>: The Examiner respectfully requests that the Applicant assign each variable the appropriate value when electing a species (i.e., X = hydrogen; Z = nitrogen; Y = -CH3; etc.) and state which claims are drawn to the elected species.

- 2. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 3. A telephone call was not made to request an oral election to the above restriction requirement due to the complexity of the restriction.

Application/Control Number: 09/534,893

Art Unit: 1619

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be

traversed (37 CFR 1.143).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. L. Jones whose telephone number is (703) 308-4640. The examiner can normally be reached on Mon.-Fri. (alternate Mon.), 6:45 a.m. - 4:15 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Diana Dudash can be reached on (703) 308-2328. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Primary Examiner
Art Unit 1619

June 18, 2001

Page 3